Summary
Quest Diagnostics Incorporated (DGX) reported its second-quarter 2022 financial results, showing a decrease in net revenues to $2.45 billion, down 3.8% year-over-year, primarily driven by a decline in COVID-19 testing services, partially offset by growth in its base business and recent acquisitions. The company's diluted earnings per share also saw a significant decrease to $1.96 from $4.96 in the prior year period. Despite the revenue dip, Quest Diagnostics demonstrated operational improvements through its Invigorate program, aiming for cost reductions and productivity enhancements. The company's balance sheet remains solid, with substantial cash and cash equivalents and significant borrowing capacity. However, the declining COVID-19 testing revenue presents an ongoing challenge that the company is navigating by focusing on its core diagnostic information services and strategic growth initiatives.
Financial Highlights
57 data points| Revenue | $2.45B |
| Cost of Revenue | $1.61B |
| Gross Profit | $842.00M |
| SG&A Expenses | $422.00M |
| Operating Expenses | $2.06B |
| Operating Income | $388.00M |
| Interest Expense | $38.00M |
| Net Income | $234.00M |
| EPS (Basic) | $2.00 |
| EPS (Diluted) | $1.96 |
| Shares Outstanding (Basic) | 117.00M |
| Shares Outstanding (Diluted) | 119.00M |
Key Highlights
- 1Net revenues for the three months ended June 30, 2022, decreased by 3.8% to $2.45 billion compared to $2.55 billion in the prior year.
- 2Diluted earnings per share attributable to Quest Diagnostics' common stockholders decreased to $1.96 for the three months ended June 30, 2022, from $4.96 in the same period last year.
- 3The decrease in revenue was primarily due to a 35% decline in COVID-19 testing revenues, which fell to $355 million from $511 million year-over-year.
- 4Base business revenues (excluding COVID-19 testing) grew by 3.3% year-over-year for the quarter, indicating resilience in core operations.
- 5Cost of services increased by 2.9% to $1.61 billion, mainly due to higher compensation and benefits costs, and additional costs from acquisitions.
- 6The company repurchased $550 million of its common stock in the first six months of 2022, continuing its capital return strategy.
- 7Net cash provided by operating activities for the six months ended June 30, 2022, was $882 million, a decrease from $1.19 billion in the prior year period.